Raphaël Scharfmann Inserm Research Director Inserm Unit 1016 – Institut Cochin A partner in the HumEn project email@example.com
A €6 million grant awarded to the HumEn project by the European Commission has helped bring together the main institutes carrying out stem cell research, including Inserm, and European industrial partners wishing to develop insulin-producing cells as a future cell replacement therapy for diabetes.
The complete maturation of human pluripotent stem cells into transplantable beta cells* that may cure diabetes has not yet been achieved in the laboratory.
The objective of the HumEn project is to develop functional insulin-producing beta cells, which are lacking in people with diabetes,* from pluripotent stem cells. The advantage of pluripotent stem cells as a source of beta cells is that, in theory, they represent an unlimited source of insulin-producing cells.
The HumEn project, funded by the European Commission and coordinated by the University of Copenhagen, brings together six institutional partners, including Inserm, and three industrial partners. Together, they bring their expertise in complementary research sectors such as the development and physiology of beta cells, beta cell transplantation, biology of human pluripotent stem cells, polymer chemistry, specialised engineering and epigenetics. The ultimate objective is to develop functional beta cells that produce insulin and respond to glucose, and to enable patients to benefit from these advances in treatment as early as possible.
*Stem cells in diabetes treatment
A deficiency of insulin underlies all forms of diabetes, and currently affects 366 million individuals worldwide. In Europe, the number of people with diabetes is estimated at 52.8 million.
Beta cells play a central role in diabetes. They are located in the pancreas and produce insulin, the hormone that controls the transport of energy in the form of glucose to the muscles via the bloodstream. In type 1 diabetes, the immune system destroys the beta cells, whereas in type 2 diabetes, sensitivity to insulin is reduced, causing the body to require increasingly larger quantities of insulin, which the beta cells cannot secrete.
At present, the only solution for replacing destroyed or dysfunctional beta cells is transplantation with a complete pancreas or with islets of functional cells. Only a small number of patients qualify for this treatment, because of the shortage of donors.
The HumEn project is supported through the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n° HEALTH-F4-2013-602889
Partners in the HumEn project:
DanStem, University of Copenhagen, UCPH, Denmark
Helmholtz Zentrum München, German Research Center for Environmental Health, HMGU, Germany
University of Edinburgh, UEDIN, United Kingdom
Inserm – Institut Cochin, France
Department of Immunology, Genetics and Pathology (IGP), University of Uppsala, UU, Sweden
Developmental Genetics, Max Planck Institute for Heart and Lung Research, MPG, Germany
CYTOO SA, France
MATERIOMICS, The Netherlands
HumEn is becoming part of a vast European consortium working on stem cells
At the same time, the European Commission has just awarded grants to support seven research projects on stem cells. HumEn has already been able to establish collaborations with the PluriMes, Neurostemcellrepair and ThymiStem projects. Together these projects enable Europe to remain at the forefront of stem cell research, in order to create new commercial opportunities and improve the competitiveness of the European biomedical sector.
Face à l’apparition des variants du SARS-COV2, de nouvelles projections concernant la dynamique épidémique sont nécessaires pour accompagner les politiques publiques. D'après les derniers scénarios élaborés par les chercheurs de l’Inserm sous la direction de Vittoria Colizza, le variant « britannique ...
Based on a retrospective analysis of serum samples from over 9,000 adults participating in the French cohort Constances, a study by Inserm researchers found that out of the 353 participants with positive SARS-CoV-2 antibody tests, 13 had had their samples taken between ...